| Autor: |
Reerink, O, Mulder, NH, Verschueren, RCJ, Wiggers, T, Szabo, BG, Hospers, GAP |
| Přispěvatelé: |
Guided Treatment in Optimal Selected Cancer Patients (GUTS) |
| Jazyk: |
angličtina |
| Rok vydání: |
2005 |
| Předmět: |
|
| Zdroj: |
Anticancer Research, 25(1B), 629-633. INT INST ANTICANCER RESEARCH |
| ISSN: |
0250-7005 |
| Popis: |
Background: The aim was to determine the maximum tolerable dose of oxaliplatin added to (oral) 5FU in irresectable rectal cancer. Patients and Methods: Nineteen patients were treated; 13 patients received 5FU/LV and 6 patients capecitabine. Oxaliplatin was administered on days 1 and 29 at dose levels 85 and 130 mg/m(2). Four to seven weeks thereafter, surgery was performed. Results: In 6 patients treated with 85 mg/m(2) one grade 3 elevation of liver transaminases occurred. Of 7 patients who received 130 mg/m(2) 1 patient experienced a grade III thrombocytopenia and 1 patient died of neutropenic fever, probably due to an urosepsis. Six patients were treated with capecitabine, of whom 3 developed a grade III gastrointestinal toxicity. An R0 resection could be performed in 93%, a pT0-2N0 in 39%, with 2 pCR's. Conclusion: The addition of oxaliplatin at 85 mg/m(2) on days I and 29 to radiotherapy and 5FU/LV or capecitabine in irresectable rectal cancer is feasible. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
